<DOC>
	<DOCNO>NCT01404637</DOCNO>
	<brief_summary>The purpose study compare efficacy safety tamsulosin 0.4mg ( Harnal® D. 0.2mg , 2T ) tamsulosin 0.2mg ( Harnal® D 0.2mg , 1T ) patient severe symptomatic benign prostatic hyperplasia first line therapy .</brief_summary>
	<brief_title>Effects Tamsulosin 0.4mg Clinical Outcomes Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Severe LUTS : IPSS ≥ 20 Post void residual urine ≥ 150mL Patients perform catheterization Urinary tract infection patient Patients take 5 alpha reductase inhibitor Known hypersensitivity tamsulosin History postural hypotension syncope Hypertension patient treat alpha1blockers Patients newly take anticholinergic medication within 1 month Hepatic insufficiency ( AST/ALT ≥ 2 time normal range ) Renal insufficiency ( sCr ≥ 2mg/dL )</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>